Current NDC auxiliary source row compounder:4699

This page is keyed by dataset, FDA.report source record ID, and physical source row number. Empty values are shown rather than omitted.

Complete normalized row#

Record Source: ndc_compounder_zip
Product Ndc Raw: 81483-0041
Product Ndc: 81483-0041
Product Ndc Digits: 814830041
Product Type Name: HUMAN COMPOUNDED DRUG
Proprietary Name: Avastin
Proprietary Name Suffix: [empty]
Nonproprietary Name: Bevacizumab
Dosage Form Name: INJECTION, SOLUTION
Route Name: INTRAVITREAL
Marketing Category Name: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
Labeler Name: Tailstorm Health INC
Establishment Name: Tailstorm Health INC
Establishment Fei: [empty]
Substance Name: BEVACIZUMAB
Active Ingredients Info: 1.25 mg/.05 mL
History Active Ingredients Raw: BEVACIZUMAB
History Active Ingredients Info Raw: 1.25 mg/.05 mL
History Dosage Raw: INJECTION, SOLUTION
Dea Schedule: [empty]
Package Ndc Raw: 81483-0041-5
Package Ndc: 81483-0041-5
Package Ndc Digits: 8148300415
Package Ndc11: 81483004105
Package Description: 5 SYRINGE, GLASS in 1 TRAY (81483-0041-5) > .05 mL in 1 SYRINGE, GLASS (81483-0041-1)
Reporting Period Raw: 2025-2
Reporting Period: 2025-2
Normalization Status: valid
Source Url: https://www.accessdata.fda.gov/cder/compounders_ndc_directory.zip
Source Archive: compounders_ndc_directory.zip
Source File: compounders_ndc_directory.txt
Source Date: 2026-09-18
Source Last Modified: Fri, 18 Sep 2026 15:17:23 GMT
Source Archive Sha256: 222f6800f79cb1a0fa79431b7226bd6b34899999dbf086af51004a96774ada98
Source Member Sha256: f8d9743e5616579a34d614887e86a53913efa0a63d3138d59d2f87cbb4d0cc17
Source Record Id: compounder:4699
Source Row Number: 4699
Source Row Hash: 245751c52ce32d628dbb30acfd76554ee53744c8f5765cb6af110e58951bed07
Import Run Id: 20261026T055812Z
Loaded At: 2026-10-26 06:02:33

Exact raw FDA source fields#

{
    "ROUTENAME": "INTRAVITREAL",
    "PRODUCTNDC": "81483-0041",
    "DEASCHEDULE": "",
    "LABELERNAME": "Tailstorm Health INC",
    "SUBSTANCENAME": "BEVACIZUMAB",
    "DOSAGEFORMNAME": "INJECTION, SOLUTION",
    "NDCPACKAGECODE": "81483-0041-5",
    "PRODUCTTYPENAME": "HUMAN COMPOUNDED DRUG",
    "PROPRIETARYNAME": "Avastin",
    "REPORTINGPERIOD": "2025-2",
    "NONPROPRIETARYNAME": "Bevacizumab",
    "PACKAGEDESCRIPTION": "5 SYRINGE, GLASS in 1 TRAY (81483-0041-5)  > .05 mL in 1 SYRINGE, GLASS (81483-0041-1) ",
    "ACTIVEINGREDIENTSINFO": "1.25 mg/.05 mL",
    "MARKETINGCATEGORYNAME": "OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)",
    "PROPRIETARYNAMESUFFIX": ""
}

Normalization notes#

[]

Current status projection#

Dataset: compounder
Record Source: ndc_compounder_zip
Source Record Id: compounder:4699
Source Row Number: 4699
Status Scope: package
Lookup Ndc: 81483-0041-5
Lookup Ndc Digits: 8148300415
Product Ndc: 81483-0041
Product Ndc Digits: 814830041
Package Ndc: 81483-0041-5
Package Ndc Digits: 8148300415
Package Ndc11: 81483004105
Product Id: [empty]
Status Code: COMPOUNDER
Status Label: Outsourcing facility compounded drug report
Reporting Period Raw: 2025-2
Reporting Period: 2025-2
Source Table: fda_ndc_aux_compounder
Source File: compounders_ndc_directory.txt
Source Date: 2026-09-18
Source Row Hash: 245751c52ce32d628dbb30acfd76554ee53744c8f5765cb6af110e58951bed07
Import Run Id: 20261026T055812Z
Loaded At: 2026-10-26 06:02:33